Details for Patent: 5,856,336
✉ Email this page to a colleague
Summary for Patent: 5,856,336
| Title: | Quinoline type mevalonolactones |
| Abstract: | A compound of the formula ##STR1## Z=--CH(OH)--CH.sub.2 --CH(OH)--CH.sub.2 --COO.1/2Ca have HMG--CoA inhibiting effects, making them useful as inhibitors of cholesterol biosynthesis. The compound may be prepared as a pharmaceutical for reducing hyperlipidemia, hyperlipoproteinemia or atherosclerosis. |
| Inventor(s): | Fujikawa; Yoshihiro (Funabashi, JP), Suzuki; Mikio (Funabashi, JP), Iwasaki; Hiroshi (Funabashi, JP), Sakashita; Mitsuaki (Shiraoka-machi, JP), Kitahara; Masaki (Shiraoka-machi, JP) |
| Assignee: | Nissan Chemical Industries Ltd. (Tokyo, JP) |
| Application Number: | 07/883,398 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 5,856,336 |
|
Patent Claim Types: see list of patent claims | Compound; Use; |
Drugs Protected by US Patent 5,856,336
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 5,856,336
International Family Members for US Patent 5,856,336
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | 114645 | ⤷ Try a Trial | |||
| Canada | 1336714 | ⤷ Try a Trial | |||
| Germany | 3852243 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
